



ALL 143CP3

FILE COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zaghouani )  
Serial No. : 09/873,901 )  
Filed : June 4, 2001 )  
For : Coupling Of Peripheral Tolerance To )  
Endogenous IL-10 Promotes Effective )  
Modulation Of T Cells And Ameliorates )  
Autoimmune Disease )  
Examiner : Nolan )  
Group Art Unit : 1644 )

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on

10/16/03  
  
John Wurst

COMMISSIONER FOR PATENTS  
P. O. Box 1450  
Alexandria, VA 22313-1450

ATTN: OFFICE OF INITIAL PATENT EXAMINATION  
CUSTOMER SERVICE CENTER

Sir or Madam:

Applicant hereby respectfully requests that the official Filing Receipt for the patent application listed above be corrected as follows:

Domestic Priority Data as claimed by applicant:

This appln claims priority to U.S. Provisional Patent Application  
60/209,527 filed June 5, 2000 and is a CIP of PCT/US99/15225  
filed 07/06/1999

A copy of the Filing Receipt with the corrections indicated in red ink is enclosed. Please forward the corrected filing receipt to:

John Wurst  
Alliance Pharmaceutical Corp.  
6175 Lusk Blvd.  
San Diego, CA 92121

Please call the undersigned at the number stated below if there are any questions concerning this filing.

Date: 10/16/03


Respectfully submitted,

John Wurst  
Registration No. 40,283  
(858) 410-5174

ALLIA 143CP3 SN  
NAI/DOH/SGJ



UNITED STATES  
PATENT AND  
TRADEMARK OFFICE



RECEIVED  
Page 1 of 2  
OCT 27 2003  
TECH CENTER 1600/2900

Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/873,901	06/04/2001	1644	966	ALLIA.143CP3	45	65	6

20995  
KNOBBE MARTENS OLSON & BEAR LLP  
2040 MAIN STREET  
FOURTEENTH FLOOR  
IRVINE, CA 92614

CONFIRMATION NO. 5455  
UPDATED FILING RECEIPT  
  
\*OC000000009548562\*

Date Mailed: 02/24/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Habib Zaghouani, Knoxville, TN;

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/209,527/06/05/2000  
and said 60/209,517  
is a CIP of PCT/US99/15225 07/06/1999

This appln claims priority  
to U.S. Provisional Patent Application  
60/209,527 filed June 5, 2000  
and is a CIP of PCT/US99/15225  
filed 7/06/1999

**Foreign Applications**

If Required, Foreign Filing License Granted: 08/03/2001

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***

**Title**

Coupling of peripheral tolerance to endogenous IL-10 promotes effective modulation of T cells  
and ameliorates autoimmune disease

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**


The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



EALLIA143.CP3

PATENT

**COUPLING OF PERIPHERAL TOLERANCE TO ENDOGENOUS IL-10  
PROMOTES EFFECTIVE MODULATION OF T CELLS AND AMELIORATES  
AUTOIMMUNE DISEASE**

Related Applications

10 This application claims priority to U.S. Provisional Patent Application Serial  
Number 60/209,527, filed June 5, 2000 and is a continuation-in-part of International  
Application Number PCT/US99/15225, filed July 6, 1999, the disclosures of which are  
incorporated herein by reference in their entireties.

Field of the Invention

15 The present invention generally relates to compounds, compositions and methods  
for the effective endocytic presentation of immunosuppressive factors. More  
particularly, the present invention is directed to compounds, methods and compositions  
comprising immunosuppressive factors that are useful for the treatment of various  
disorders including, but not limited to, autoimmune disorders. In preferred embodiments  
the immunosuppressive factors may be T cell receptor antagonists or agonists. Other  
20 embodiments of the invention provide for the induction of tolerance in neonates or  
infants. Further embodiments provide compositions comprising immunoglobulins or  
portions thereof linked to antigens, wherein the immunoglobulins or portions thereof are  
capable of crosslinking Fc receptors present on the cell surfaces of antigen presenting  
cells. Other embodiments relate to methods of increasing the levels of IL-10 in an  
25 individual in need thereof. Still further embodiments relate to methods of stimulating  
peripheral tolerance and/or bystander suppression in an individual in need thereof. Other  
embodiments relate to methods of reducing the level of IFN $\gamma$  in an individual in need  
thereof. In further embodiments, the present invention provides compositions which  
facilitate the presentation of an autoantigen by antigen presenting cells which lack or  
30 have a reduced level of costimulatory molecules.